EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Chimeric Antigen Receptor T‐Cell Therapy: More Than an Anti‐Cancer Drug

Hannah C M Schenk iD, Ilse Gille iD, Carolt Arana, Jordi Rovira iD, Eduard Palou, Fritz Diekmann, Dave L Roelen iD, Mirjam H M Heemskerk, Sebastiaan Heidt iD

HLA · 2026

DOI: 10.1111/tan.70550 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift HLA, 2026. Verfasst von Hannah C M Schenk und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Autoimmune Diseases, Receptors, Antigen, T-Cell. Die Arbeit nennt 248 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Nierstichting, Redes de Investigación Cooperativa Orientadas a Resultados en Salud, Instituto de Salud Carlos III-Subdirección General de Evaluación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Initially, chimeric antigen receptor (CAR) T‐cell therapy was developed to eliminate malignant B cells in haematological B‐cell malignancies by targeting CD19 and B‐cell maturation antigen. This approach achieved notable success, resulting in (malignant) B‐cell depletion and inducing clinical remission in cancer patients. The scope of CAR T‐cell therapy has since expanded to various other applications. Recently, CD19‐directed CAR T cells have shown promising results in treating B‐cell‐mediated autoimmune diseases, with patients experiencing long‐lasting symptom cessation. Despite these advancements, the unselective targeting of both pathogenic and protective B cells calls for precise immunotherapies capable of selectively removing pathogenic B cells. Therefore, antigen‐specific CARs were designed to specifically interact with and deplete subpopulations of target cells expressing the target antigens. Subsequently, modified CARs were introduced by incorporating autoantigens into the sequence, which allowed antigen‐specific B cells to bind to CAR T cells. Additionally, antigen‐specific CAR T cells have been exploited to treat viral infections. Moreover, CAR technology was expanded to regulatory T cells (Tregs), where CARs can be adopted to induce a tolerogenic environment in target tissues, offering new possibilities in autoimmune diseases, as well as prevention of graft‐versus‐host disease in haematopoietic stem cell transplantation and transplant rejection in the setting of solid organ transplantation. Although CAR T cells and CAR Tregs are promising and broadly explored, safety issues must be addressed and possible solutions thoroughly investigated. This review outlines the broad potential of CAR‐based therapies in autoimmunity, virology and transplantation while addressing the need for solutions to current safety issues.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenImmunotherapy, AdoptiveAutoimmune DiseasesReceptors, Antigen, T-CellVirus DiseasesHumansB-LymphocytesAntigens, CD19T-Lymphocytes, RegulatoryAnimalsT-Lymphocytes

Stichwörter der Autor:innen

CAR (chimeric antigen receptor)autoimmunitycellular therapyinfectiontransplantation

Substanzen

Receptors, Chimeric AntigenAntigens, CD19Receptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Immunology, Leiden University Medical Center, Leiden, the Netherlands.
  • Laboratori Experimental de Nefrologia i Trasplantament (LENIT), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Department of Nephrology and Kidney Transplantation, Institut Clínic de Nefrologia i Urologia (ICNU), Hospital Clínic de Barcelona, Barcelona, Spain.
  • Universitat de Barcelona, Barcelona, Spain.

ORCID-Profile: Hannah C M Schenk, Ilse Gille, Jordi Rovira, Dave L Roelen, Sebastiaan Heidt

Förderung

  • Nierstichting
  • Redes de Investigación Cooperativa Orientadas a Resultados en Salud
  • Instituto de Salud Carlos III-Subdirección General de Evaluación

Zitieren

APA

Schenk, H. C. M., Gille, I., Arana, C., Rovira, J., Palou, E., Diekmann, F., Roelen, D. L., Heemskerk, M. H. M., & Heidt, S. (2026). Chimeric Antigen Receptor T‐Cell Therapy: More Than an Anti‐Cancer Drug. HLA. https://doi.org/10.1111/tan.70550

Vancouver

Schenk HCM, Gille I, Arana C, Rovira J, Palou E, Diekmann F, et al. Chimeric Antigen Receptor T‐Cell Therapy: More Than an Anti‐Cancer Drug. HLA. 2026. doi:10.1111/tan.70550

BibTeX
@article{Schenk2026,
  author = {Schenk, Hannah C M and Gille, Ilse and Arana, Carolt and Rovira, Jordi and Palou, Eduard and Diekmann, Fritz and Roelen, Dave L and Heemskerk, Mirjam H M and Heidt, Sebastiaan},
  title = {Chimeric Antigen Receptor T‐Cell Therapy: More Than an Anti‐Cancer Drug},
  journal = {HLA},
  year = {2026},
  doi = {10.1111/tan.70550}
}
Kostenlos starten →